Evidence map›Paper›PMID 23824624›Full record

Trial reportInternational journal of cancer2014

Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.

Jill Koshiol, Martha Sklavos, Nicolas Wentzensen, Troy Kemp, Mark Schiffman, S Terence Dunn, Sophia S Wang, Joan L Walker, Mahboobeh Safaeian, Rosemary E Zuna and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Cytokines: From Clinical Significance to Quantification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Jill KoshiolDivision of Cancer Epidemiology and Genetics, NCI/NIH/DHHS, Bethesda, MD.
Martha Sklavos
Nicolas Wentzensen
Troy Kemp
Mark Schiffman
S Terence Dunn
Sophia S Wang
Joan L Walker
Mahboobeh Safaeian
Rosemary E Zuna
Allan Hildesheim
Ruth M Pfeiffer
Ligia A Pinto
University of Oklahoma Health Sciences Center · USDepartment of Health and Human Services · USDivision of Cancer Epidemiology and GeneticsFrederick National Laboratory for Cancer Research · USUnited States Department of Health and Human Services · USCity of Hope · USScience Applications International Corporation (United States) · US

Funding

HPV, cervical neoplasia, and vaccinationZIACP010210 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KREIMER, AIMEE · 2010 to 2025
$5.4M
Intramural NIH HHS Z99 CA999999NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

Although persistent carcinogenic human papillomavirus (HPV) infection is necessary for cervical carcinogenesis, the cofactors involved in HPV persistence and disease progression are poorly understood. Chronic cervical inflammation may increase risk, but few studies have measured immune markers (cytokines, chemokines and soluble receptors) in cervical secretions. We evaluated the performance of 74 multiplexed, bead-based immune markers in cervical secretions from three groups of women with biopsy evaluation of cervical intraepithelial neoplasia (CIN), (i) <CIN1, HPV-negative (n = 24), (ii) <CIN1, carcinogenic HPV-positive (n = 24) and (iii) CIN2/3, carcinogenic HPV-positive (n = 48), matched on time since last period and smoking status. We considered markers with >25% detectability and >80% interclass correlation coefficients (ICCs) acceptable for epidemiologic studies. Within-batch coefficients of variation (CVs) of ≥25% indicated room for assay improvement. Secondarily, we explored associations between marker levels and CIN/HPV status adjusted for matching variables, assay batch, age and number of sexual partners. Sixty-two markers (84%) had >25% detectability and ICCs > 80%. Of those, 53 (85%) had CVs < 25%. Using these preliminary data, we found that HPV positivity was associated with increased eotaxin-1 [odds ratio (OR): 15.63, 95% confidence interval (CI): 1.26-200.00] and G-CSF (OR: 12.99, 95% CI: 1.10-142.86) among CIN-negative women. There was suggestive evidence that higher chemoattractant marker levels were associated with CIN2/3 (e.g., MIP-1delta, OR: 4.48, 95% CI: 0.87-23.04 versus <CIN1/HPV-positive). More than 70% of markers were reliably measured. This assay may be used to evaluate associations of immune-related markers with CIN and HPV status.

Indexed as

AdultBiomarkersDisease ProgressionFemaleFollow-Up StudiesHumansLuminescent MeasurementsNeoplasm StagingPapillomaviridaePapillomavirus InfectionsPrognosisUterine Cervical DysplasiaUterine Cervical NeoplasmsYoung AdultBiomarkerscervical intraepithelial neoplasiacervical secretionshuman papillomavirusimmunology

Identifiers

PMID23824624
PMCPMC3872247
OpenAlexW1558952104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.